A phase II trial of recombinant human interferon-gamma and recombinant tumor necrosis factor in patients with advanced gastrointestinal malignancies: results of a trial terminated by excessive toxicity.

Published

Journal Article

Recombinant human tumor necrosis factor and recombinant human interferon-gamma are two representatives of a novel class of antineoplastic agents. Evaluation of these agents in vitro has suggested that the combination would be more effective than either agent alone. A prior phase I study demonstrated that the maximum tolerated dose for each agent was 150 micrograms/m2/day for 5 days when administered concomitantly. Based on this experience, a phase II trial of patients with biliary tract, pancreatic, and colorectal cancer was planned. Our goal was to treat a minimum of 14 patients with each tumor type. However, in the first 13 patients entered into this trial the toxic effects at the starting doses of 125 micrograms/m2/day for 5 days for each agent were intolerable, with four patients unable to complete planned therapy. In this cohort of patients, no objective responses were observed. Further clinical investigation of this combination should consider alternative treatment schedules to reproduce the in vitro synergistic cytotoxicity of this combination while minimizing host toxicity.

Full Text

Duke Authors

Cited Authors

  • Abbruzzese, JL; Levin, B; Ajani, JA; Faintuch, JS; Pazdur, R; Saks, S; Edwards, C; Gutterman, JU

Published Date

  • October 1990

Published In

Volume / Issue

  • 9 / 5

Start / End Page

  • 522 - 527

PubMed ID

  • 2123922

Pubmed Central ID

  • 2123922

International Standard Serial Number (ISSN)

  • 0732-6580

Language

  • eng

Conference Location

  • United States